Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
Globe Newswire•11/10/2026•13:00 ET
0
Key Highlights
- ➤Updated SimpleScreen CRC raised advanced precancerous lesion sensitivity to 18.2%
- ➤High-grade dysplasia sensitivity improved to 41.9% from 30.5%
- ➤CRC detection reached 80.4% sensitivity at 90% specificity
- ➤Abbott launched first-generation SimpleScreen CRC commercially in late September
- ➤Freenome will present updated validation data at ACG 2026 on Oct. 14
Expert Statements
Aaron Elliott, CEO of Freenome
“These results suggest that our blood-based screening test may detect precancerous lesions with clinically meaningful sensitivity.”
Aaron Elliott, CEO of Freenome
“The ability to continually improve performance through refinements to our assay and algorithm, as seen with these results, is a fundamental part of our up-versioning strategy.”
Aaron Elliott, CEO of Freenome
“We believe this iterative methodology not only improves CRC APL performance but is also applicable across our multi-cancer pipeline.”
Aaron Elliott, CEO of Freenome
“Combined with our personalized cancer detection approach, this is how we continue to expand blood-based screening into an accessible option for the millions of Americans who remain unscreened.”
– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention –
– Overall detection of colorectal cancer remained consistent with test’s first version, achieving 80.4% sensitivity at 90% specificity –
Get started
Create a free account to read the full story.